(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

ANTICORPOS ANTI-LIV1 HUMANIZADOS PARA O TRATAMENTO DE CÂNCER

ArquivadaInvention PatentPCT · US2021071609

Application data

Number

112023005196

Type

Invention Patent

Filing

09/27/2021

Publication

05/30/2023

PCT

US2021071609

Progress at the INPI

  1. Filing09/27/21
  2. Publication05/30/23
  3. Abandoned
  4. Allowance
  5. Grant
  6. In force

The application was abandoned: examination was not requested within the 36 months following the 09/27/2021 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.

Talk to a specialist

Latest action published by the INPI: 12/24/2024. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

SEAGEN INC.

US

See this company's full portfolio

Inventors

H. L. (pessoa física)

US

M. O. (pessoa física)

US

Z. W. (pessoa física)

US

Technical data

Priority claims

US

63/084,444 · 09/28/2020

US

63/243,025 · 09/10/2021

Abstract

ANTICORPOS ANTI-LIV1 HUMANIZADOS PARA O TRATAMENTO DE CÂNCER.São providos métodos para usar anticorpos anti-LIV1 e conjugados anticorpo-fármaco, incluindo conjugados anticorpo-fármaco anti-LIV1, para inibir a proliferação de uma célula, bem como para o tratamento de cânceres, tais como, por exemplo, câncer de próstata e melanoma.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Arquivamento definitivo - Art. 33 da LPI

#11.1.1

12/24/2024

RPI 2816

Arquivamento - Art. 33 da LPI

#11.1

10/08/2024

RPI 2805

Notificação de entrada na fase nacional - PCT

#1.3

05/30/2023

RPI 2734

Alteração de dados cadastrais

#1.1

03/28/2023

RPI 2725

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.